Liquidia Corp Dossier
Qualitative Analysis
Business overview
Liquidia Corp (NASDAQ: LQDA) is a commercial-stage biopharmaceutical company focused on developing, manufacturing, and commercializing innovative therapies for patients with challenging rare cardiopulmonary diseases. The company utilizes its proprietary PRINT (Liquidia's particle engineering platform) technology to engineer uniform drug particles with precise control over size, three-dimensional geometric shape, and chemical composition. Liquidia's lead commercial product is YUTREPIA (treprostinil) inhalation powder, an inhaled dry-powder formulation of treprostinil approved by the FDA in May 2025 for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Additionally, the company is developing L606, an investigational liposomal formulation of treprostinil currently in Phase 3 clinical trials for PAH and PH-ILD.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding the specialized sales force from 48 to 64 representatives to deepen prescriber adoption, target high-prescribing physicians, and educate the PH-ILD community [1.3.4].
Expected impact: Aims to capture a larger share of the $4.5 billion addressable PAH and PH-ILD market, driving annualized revenues toward $1.0 billion by 2027.
Advancing L606, an investigational liposomal formulation of treprostinil administered twice daily, into the pivotal Phase 3 RE-SPIRE study and exploring broader indications.
Expected impact: Establishes a highly differentiated, twice-daily nebulized therapy to capture market share from short-acting alternatives.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Liquidia holds exclusive rights to conduct commercial activities for Treprostinil Injection in the United States, working jointly with Sandoz on commercial strategy while Sandoz holds the ANDA [1.1.1].
Terms: Liquidia receives a portion of the net profits generated from the sales of Treprostinil Injection
Collaborating to leverage drug delivery technologies and enhance Liquidia's innovative pipeline, particularly supporting the development of L606.
Terms: Liquidia paid an upfront license fee of $10 million, with Pharmosa eligible to receive up to $215 million in development and sales milestones for PAH and PH-ILD indications, plus low double-digit royalties on net sales. The agreement was later expanded with an additional $3.5 million upfront and up to $157.75 million in milestones for territories outside North America.